A First-in-Class High-Throughput Screen to Discover Modulators of the Alternative Lengthening of Telomeres (ALT) Pathway
- 13 August 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 7 (9) , 2799-2819
Abstract
Telomeres are a protective cap that prevents chromosome ends from being recognized as double-stranded breaks. In somatic cells, telomeres shorten with each cell division due to the end replication problem, which eventually leads to senescence, a checkpoint proposed to prevent uncontrolled cell growth. Tumor cells avoid telomere shortening by activating one of two telomere maintenance mechanisms (TMMs): telomerase reactivation or alternative lengthening of telomeres (ALT). TMMs are a viable target for cancer treatment as they are not active in normal, differentiated cells. Whereas there is a telomerase inhibitor currently undergoing clinical trials, there are no known ALT inhibitors in development, partially because the complex ALT pathway is still poorly understood. For cancers such as neuroblastoma and osteosarcoma, the ALT-positive status is associated with an aggressive phenotype and few therapeutic options. Thus, methods that characterize the key biological pathways driving ALT will provide important mechanistic insight. We have developed a first-in-class phenotypic high-throughput screen to identify small-molecule inhibitors of ALT. Our screen measures relative C-circle level, an ALT-specific biomarker, to detect changes in ALT activity induced by compound treatment. To investigate epigenetic mechanisms that contribute to ALT, we screened osteosarcoma and neuroblastoma cells against an epigenetic-targeted compound library. Hits included compounds that target chromatin-regulating proteins and DNA damage repair pathways. Overall, the high-throughput C-circle assay will help expand the repertoire of potential ALT-specific therapeutic targets and increase our understanding of ALT biology.Keywords
Funding Information
- National Cancer Institute (R03CA252796)
- Amgen Foundation
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill (P30CA016086)
This publication has 104 references indexed in Scilit:
- Integrated multiomic analysis and high‐throughput screening reveal potential gene targets and synergetic drug combinations for osteosarcoma therapyMedcomm, 2023
- Native FISH: A low- and high-throughput assay to analyze the alternative lengthening of telomere (ALT) pathway2022
- Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine TumorsEndocrine Pathology, 2022
- Extensive Proliferation of Human Cancer Cells with Ever-Shorter TelomeresCell Reports, 2017
- Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of GlioblastomaCancer Cell, 2012
- Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A)Bioorganic & Medicinal Chemistry Letters, 2012
- Association of Age at Diagnosis and Genetic Mutations in Patients With NeuroblastomaJAMA, 2012
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- The telomere hypothesis of cellular agingExperimental Gerontology, 1992
- Identification of a specific telomere terminal transferase activity in tetrahymena extractsCell, 1985